Other
Payments to Acquire Debt Securities, Available-for-Sale
Gilead Sciences Payments to Acquire Debt Securities, Available-for-Sale decreased by 62.0% to $525.00M in Q1 2026 compared to the prior quarter. Over 3 years (FY 2021 to FY 2025), Payments to Acquire Debt Securities, Available-for-Sale shows relatively stable performance with a 1.3% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2020
Last reportedQ1 2026May 7, 2026
How to read this metric
Higher outflows indicate active investment in fixed-income assets, often driven by premium growth or capital deployment strategies.
Detailed definition
Represents the cash outflows used to purchase debt securities classified as available-for-sale. This reflects the compan...
Peer comparison
Standard for institutional investors and insurance companies managing float.
Metric ID:
other_payments_to_acquire_available_for_sale_securities_debtHistorical Data
17 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.15B | $813.00M | $626.00M | $613.00M | $477.00M | $308.00M | $372.00M | $527.00M | $578.00M | $369.00M | $456.00M | $244.00M | $0.00 | $2.00B | $270.00M | $1.38B | $525.00M |
| QoQ Change | — | -29.1% | -23.0% | -2.1% | -22.2% | -35.4% | +20.8% | +41.7% | +9.7% | -36.2% | +23.6% | -46.5% | -100.0% | — | -86.5% | +411.9% | -62.0% |
| YoY Change | — | — | — | — | -58.4% | -62.1% | -40.6% | -14.0% | +21.2% | +19.8% | +22.6% | -53.7% | -100.0% | — | — | — | — |
Range$0.00 – $2.00B
CAGR-17.7%
Avg YoY Growth-29.5%
Median YoY Growth-40.6%
Payments to Acquire Debt Securities, Available-for-Sale at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's payments to acquire debt securities, available-for-sale?
- Gilead Sciences (GILD) reported payments to acquire debt securities, available-for-sale of $525.00M in Q1 2026.
- What is the long-term trend for Gilead Sciences's payments to acquire debt securities, available-for-sale?
- Over 3 years (2021 to 2025), Gilead Sciences's payments to acquire debt securities, available-for-sale has grown at a 1.3% compound annual growth rate (CAGR), from $3.52B to $3.65B.
- What does payments to acquire debt securities, available-for-sale mean?
- Cash spent to purchase debt securities intended for investment.